Trial Profile

Covid-19 Vaccine Cohort in Specific Populations

Status: Active, no longer recruiting

Phase of Trial: Phase IV

Latest Information Update: 06 Feb 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 1222 (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Pharmacodynamics
Acronyms COV-POPART

Most Recent Events

22 Feb 2023 Results(n=2014) comparing the 12-month post primary vaccination humoral immune response to mRNA COVID-19 vaccines in PLHIV and controls presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
02 Nov 2022 New trial record
13 Sep 2022 Results(n=1196 ) assessing the humoral immunogenicity of COVID-19 vaccines in patients with cancer compared to controls presented at the 47th European Society for Medical Oncology Congress

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com